Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
I'm Watching These 6 Dividend Stocks For Big Announcements
07:55am, Sunday, 05'th Apr 2026
Dividend raises mean something right now.
Bank of America sees Eli Lilly's Foundayo as preferred oral GLP-1
12:57pm, Thursday, 02'nd Apr 2026
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without c
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
08:20am, Thursday, 02'nd Apr 2026
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter results Eli Lilly and Co (NYSE:LLY) has won FDA ap
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
08:00am, Thursday, 02'nd Apr 2026
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen
Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
03:12am, Thursday, 02'nd Apr 2026
Shares in Novo Nordisk (NYSE:NVO) held firm and edged higher in early trading on Thursday despite the US Food and Drug Administration approving a new once-daily weight-loss pill from rival Eli Lilly t
Eli Lilly CEO: Our pill supply can 'reach the planet'
12:09pm, Wednesday, 01'st Apr 2026
Eli Lilly Chair & CEO Dave Ricks tells CNBC's Angelica Peebles that with the approval of the company's GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the glo
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® wit
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
11:28am, Wednesday, 01'st Apr 2026
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenienc
Lexaria to Begin New Human Clinical Study in GLP-1
09:20am, Wednesday, 01'st Apr 2026
Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
07:35am, Wednesday, 01'st Apr 2026
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech lands
Down 13% in 4 Weeks, Here's Why Global Partners (GLP) Looks Ripe for a Turnaround
10:36am, Tuesday, 31'st Mar 2026
Global Partners (GLP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
03:05am, Monday, 30'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery sys
Global Partners: Resilient High-Yield Play Trading Below Intrinsic Value
08:11am, Saturday, 28'th Mar 2026
Global Partners LP remains a Strong Buy, offering a resilient business model, robust yield, and trading at a discount to intrinsic value. GLP's distribution yield stands at ~6.76% today, with 17 conse
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
08:15am, Friday, 27'th Mar 2026
Structure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals. Aleniglipron's best-in-class oral efficacy, low disco
